Daniel C Pevear
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$7.1MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $7.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 1, 2021 | NIH | SBIR Phase II Advancement of antiviral inhibitors of chikungunya virus | $1.0M | VENATORX PHARMACEUTICALS INC |
| Mar 24, 2020 | NIH | SBIR Phase II Advancement of antiviral inhibitors of chikungunya virus | $1.0M | VENATORX PHARMACEUTICALS INC |
| May 14, 2019 | NIH | SBIR Phase II Advancement of antiviral inhibitors of chikungunya virus | $1.0M | VENATORX PHARMACEUTICALS INC |
| Jun 22, 2018 | NIH | SBIR Phase II Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series | $1.2M | VENATORX PHARMACEUTICALS INC |
| Jun 16, 2017 | NIH | SBIR Phase II Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series | $1.2M | VENATORX PHARMACEUTICALS INC |
| Jul 4, 2016 | NIH | SBIR Phase II Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series | $1.1M | VENATORX PHARMACEUTICALS INC |
| Feb 11, 2016 | NIH | SBIR Phase I Discovery and Advancement of Chikungunya virus inhibitors | $300K | VENATORX PHARMACEUTICALS INC |
| Jan 26, 2015 | NIH | SBIR Phase I Discovery and Advancement of Chikungunya virus inhibitors | $300K | VENATORX PHARMACEUTICALS INC |
Peer ranks
Federal funding#138
Awards as PI#190
Patents#273
Companies
- VENATORX PHARMACEUTICALS INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.